News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
867,353 Results
Type
Article (87785)
Company Profile (824)
Press Release (778728)
Multimedia
Podcasts (188)
Webinars (28)
Section
Business (233177)
Career Advice (4144)
Deals (39843)
Drug Delivery (144)
Drug Development (91368)
Employer Resources (203)
FDA (18361)
Job Trends (17415)
News (397735)
Policy (39950)
Tag
Academia (3006)
Academic (2)
Accelerated approval (28)
Adcomms (35)
Allergies (135)
Alliances (56981)
ALS (171)
Alzheimer's disease (1763)
Antibody-drug conjugate (ADC) (311)
Approvals (18485)
Artificial intelligence (583)
Autoimmune disease (136)
Automation (33)
Bankruptcy (406)
Best Places to Work (12634)
BIOSECURE Act (23)
Biosimilars (191)
Biotechnology (488)
Bladder cancer (154)
Brain cancer (62)
Breast cancer (628)
Cancer (4737)
Cardiovascular disease (413)
Career advice (3566)
Career pathing (40)
CAR-T (292)
CDC (59)
Celiac Disease (1)
Cell therapy (790)
Cervical cancer (37)
Clinical research (76623)
Collaboration (1624)
Company closure (5)
Compensation (1080)
Complete response letters (65)
COVID-19 (2980)
CRISPR (93)
C-suite (751)
Cystic fibrosis (148)
Data (5900)
Decentralized trials (2)
Denatured (69)
Depression (133)
Diabetes (501)
Diagnostics (7177)
Digital health (42)
Diversity (12)
Diversity, equity & inclusion (49)
Drug discovery (278)
Drug pricing (206)
Drug shortages (36)
Duchenne muscular dystrophy (227)
Earnings (99900)
Editorial (60)
Employer branding (25)
Employer resources (173)
Events (134578)
Executive appointments (1011)
FDA (21255)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (7)
Frontotemporal dementia (21)
Funding (1453)
Gene editing (203)
Generative AI (60)
Gene therapy (630)
GLP-1 (1089)
Government (5421)
Grass and pollen (8)
Guidances (380)
Healthcare (20941)
HIV (55)
Huntington's disease (45)
IgA nephropathy (80)
Immunology and inflammation (278)
Immuno-oncology (42)
Indications (77)
Infectious disease (3254)
Inflammatory bowel disease (198)
Inflation Reduction Act (16)
Influenza (114)
Intellectual property (220)
Interviews (816)
IPO (17944)
IRA (59)
Job creations (5198)
Job search strategy (2866)
Kidney cancer (17)
Labor market (88)
Layoffs (653)
Leadership (39)
Legal (10154)
Liver cancer (95)
Longevity (14)
Lung cancer (651)
Lymphoma (361)
Machine learning (40)
Management (66)
Manufacturing (756)
MASH (167)
Medical device (14976)
Medtech (15016)
Mergers & acquisitions (22885)
Metabolic disorders (1307)
Multiple sclerosis (152)
NASH (23)
Neurodegenerative disease (325)
Neuropsychiatric disorders (87)
Neuroscience (2973)
NextGen: Class of 2025 (7703)
Non-profit (5103)
Now hiring (62)
Obesity (627)
Opinion (327)
Ovarian cancer (153)
Pain (193)
Pancreatic cancer (206)
Parkinson's disease (275)
Partnered (36)
Patents (473)
Patient recruitment (420)
Peanut (59)
People (66659)
Pharmaceutical (145)
Pharmacy benefit managers (30)
Phase I (23663)
Phase II (33252)
Phase III (25070)
Pipeline (3998)
Policy (319)
Postmarket research (3554)
Preclinical (10669)
Press Release (72)
Prostate cancer (231)
Psychedelics (53)
Radiopharmaceuticals (291)
Rare diseases (817)
Real estate (7436)
Recruiting (80)
Regulatory (28617)
Reports (65)
Research institute (2717)
Resumes & cover letters (651)
Rett syndrome (24)
RNA editing (16)
RSV (82)
Schizophrenia (149)
Series A (244)
Series B (178)
Service/supplier (30)
Sickle cell disease (100)
Special edition (26)
Spinal muscular atrophy (174)
Sponsored (47)
Startups (4327)
State (2)
Stomach cancer (19)
Supply chain (107)
Tariffs (97)
The Weekly (117)
Vaccines (1110)
Venture capital (82)
Weight loss (437)
Women's health (79)
Worklife (21)
Date
Today (105)
Last 7 days (578)
Last 30 days (2595)
Last 365 days (33251)
2025 (32892)
2024 (38142)
2023 (42568)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51337)
2018 (39122)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1288)
Alabama (86)
Alaska (7)
Arizona (328)
Arkansas (14)
Asia (51351)
Australia (9020)
California (10889)
Canada (3184)
China (1070)
Colorado (459)
Connecticut (481)
Delaware (329)
Europe (118024)
Florida (1595)
Georgia (352)
Hawaii (3)
Idaho (68)
Illinois (903)
India (62)
Indiana (525)
Iowa (22)
Japan (388)
Kansas (130)
Kentucky (41)
Louisiana (28)
Maine (81)
Maryland (1400)
Massachusetts (8058)
Michigan (344)
Minnesota (633)
Mississippi (6)
Missouri (135)
Montana (34)
Nebraska (27)
Nevada (118)
New Hampshire (81)
New Jersey (2961)
New Mexico (32)
New York (2907)
North Carolina (1541)
North Dakota (10)
Northern California (5140)
Ohio (332)
Oklahoma (22)
Oregon (52)
Pennsylvania (2206)
Puerto Rico (20)
Rhode Island (48)
South America (1656)
South Carolina (61)
South Dakota (1)
Southern California (4183)
Tennessee (168)
Texas (1714)
United States (39588)
Utah (325)
Vermont (1)
Virginia (274)
Washington D.C. (85)
Washington State (921)
West Virginia (4)
Wisconsin (115)
Wyoming (2)
There are 867,353 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Rosalind Franklin University Secures $1.7M in NIH Funding to Advance Research on Social Recognition Mechanisms in Schizophrenia and Autism Spectrum Disorders
December 19, 2025
·
1 min read
Layoff Tracker
Voyager Loses 30 Employees After Novartis Prunes Deal
Follow along as
BioSpace
tracks job cuts and restructuring initiatives.
December 19, 2025
·
98 min read
·
BioSpace Editorial Staff
Rare diseases
Kyowa Kirin Could Get Windfall From Updated Newborn Screening Recommendations
A report from analysts at Jefferies suggested that new screenings for metachromatic leukodystrophy and Duchenne muscular dystrophy could bump sales of the gene therapy Libmeldy by more than $100 million.
December 19, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
Cibus Therapeutics Announces Strategic Partnership with Mission: Cure and Greenstone Biosciences to Accelerate Development of CBT-101, a Novel Therapy for Chronic Pancreatitis
December 19, 2025
·
1 min read
Mergers & acquisitions
BioMarin Pumps Up Revenue Goals With $4.8B Amicus Purchase
BioMarin Pharmaceutical has faced a rocky road, promising and then backing off revenue targets and cutting assets that have underperformed. But Amicus’ rare disease portfolio is already bringing in $600 million annually.
December 19, 2025
·
2 min read
·
Dan Samorodnitsky
Cardiovascular disease
Cytokinetics’ Moment of Truth: Can Aficamten Take On BMS in Hypertrophic Cardiomyopathy?
After 27 years in business, Cytokinetics hopes to pit its own cardiac myosin inhibitor against one it initially developed—now owned by Bristol Myers Squibb—in a market worth billions. Aficamten has a PDUFA date of Dec. 26.
December 19, 2025
·
5 min read
·
Dan Samorodnitsky
Infectious disease
Insmed Delivers ‘Rare Disappointment’ as Brinsupri Flops in Mid-Stage Rhinosinusitis Study
Insmed pointed to a strong placebo response as the reason for the trial’s failure.
December 19, 2025
·
2 min read
·
Tristan Manalac
ADCs
Patient Deaths Put Merck, Daiichi Sankyo’s Antibody-Drug Conjugate on Hold
The fatalities were attributed to interstitial lung disease, a known side effect of Daiichi Sankyo’s DXd-based antibody-drug conjugates. A spokesperson declined to say how many patients died.
December 19, 2025
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Takeda’s $4B Nimbus Bet Pays Off With ‘Best-in-Class’ Phase III Plaque Psoriasis Data
With zasocitinib, Takeda is looking to challenge Bristol Myers Squibb’s kinase inhibitor Sotyktu, for which the Japanese pharma is running a head-to-head study in plaque psoriasis. Takeda expects to file for zasocitinib’s FDA approval next year.
December 19, 2025
·
2 min read
·
Tristan Manalac
Press Releases
MEDIPOST Announces the Exclusive Commercialization License Agreement with Teikoku Seiyaku for Knee Osteoarthritis Treatment CARTISTEM® in Japan
December 19, 2025
·
3 min read
1 of 86,736
Next
